See more : Winson Holdings Hong Kong Limited (6812.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Vincerx Pharma, Inc. (VINCU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vincerx Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jet Airways (India) Limited (JETAIRWAYS.BO) Income Statement Analysis – Financial Results
- PT ABM Investama Tbk (ABMM.JK) Income Statement Analysis – Financial Results
- Pearl Global Limited (PG1.AX) Income Statement Analysis – Financial Results
- BSR Real Estate Investment Trust (HOM-U.TO) Income Statement Analysis – Financial Results
- The Chiba Bank, Ltd. (CHBAY) Income Statement Analysis – Financial Results
Vincerx Pharma, Inc. (VINCU)
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 915.00K | 939.00K | 340.00K | 173.00K | 173.00K |
| Gross Profit | -915.00K | -939.00K | -340.00K | -173.00K | -173.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.06M | 52.15M | 40.08M | 7.12M | 0.00 |
| General & Administrative | 13.64M | 18.95M | 22.58M | 3.60M | 54.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 44.95K |
| SG&A | 13.64M | 18.95M | 22.58M | 3.60M | 45.00K |
| Other Expenses | 0.00 | 1.24M | -8.00K | -8.00K | 0.00 |
| Operating Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Cost & Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Interest Income | 1.25M | 664.00K | 0.00 | 54.27K | 54.27K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 |
| Depreciation & Amortization | 52.00K | 939.00K | 340.00K | 5.71M | 54.00K |
| EBITDA | -42.61M | -68.67M | -62.66M | -10.71M | 9.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.61M | -73.57M | -62.66M | -10.71M | -45.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | 8.21M | 23.35M | -5.91M | 0.00 |
| Income Before Tax | -40.16M | -65.37M | -39.31M | -10.72M | -45.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.21M | -23.70M | 8.00K | -54.00 |
| Net Income | -40.16M | -57.16M | -15.61M | -10.73M | -45.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| EPS Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Weighted Avg Shares Out | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
| Weighted Avg Shares Out (Dil) | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Source: https://incomestatements.info
Category: Stock Reports